A Multi-center, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Lanadelumab (SHP643) in Chinese Subjects With Hereditary Angioedema
收藏DataCite Commons2025-09-09 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011665/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The main aim of this study is to evaluate the safety of lanadelumab in Chinese participants with HAE.Participants will be treated with lanadelumab for 26 weeks.
提供机构：
Vivli
创建时间：
2025-07-30
